128 related articles for article (PubMed ID: 11956642)
1. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker.
Kudo S; Tanaka J; Kashida H; Tamegai Y; Endo S; Yamano HO
Oncol Rep; 2002; 9(3):635-8. PubMed ID: 11956642
[TBL] [Abstract][Full Text] [Related]
2. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Dis Colon Rectum; 1992 Feb; 35(2):123-30. PubMed ID: 1735313
[TBL] [Abstract][Full Text] [Related]
3. [Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
Mitomi T; Tsuchiya S; Iijima N; Aso K; Suzuki K; Nishiyama K; Amano T; Takahashi T; Murayama N; Oka H
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2241-9. PubMed ID: 2500070
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using PSK and 5-FU.
Takahashi Y; Mai M; Nakazato H
Anticancer Res; 2005; 25(2B):1377-84. PubMed ID: 15865094
[TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
Sakai T; Yamashita Y; Maekawa T; Mikami K; Hoshino S; Shirakusa T
Cancer Biother Radiopharm; 2008 Aug; 23(4):461-7. PubMed ID: 18771350
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters.
Ohwada S; Ogawa T; Makita F; Tanahashi Y; Ohya T; Tomizawa N; Satoh Y; Kobayashi I; Izumi M; Takeyoshi I; Hamada K; Minaguchi S; Togo Y; Toshihiko T; Koyama T; Kamio M
Oncol Rep; 2006 Apr; 15(4):861-8. PubMed ID: 16525672
[TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer.
Tanaka H; Muguruma K; Ohira M; Kubo N; Yamashita Y; Maeda K; Sawada T; Hirakawa K
Anticancer Res; 2012 Aug; 32(8):3427-33. PubMed ID: 22843926
[TBL] [Abstract][Full Text] [Related]
8. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
[TBL] [Abstract][Full Text] [Related]
9. [Effect of PSK on recurrence of stage II/III gastric cancer].
Tanaka H; Muguruma K; Kubo N; Amano R; Noda E; Yamada N; Yashiro M; Maeda K; Sawada T; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2258-60. PubMed ID: 21224540
[TBL] [Abstract][Full Text] [Related]
10. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK.
Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
Anticancer Res; 1997; 17(4A):2815-8. PubMed ID: 9252721
[TBL] [Abstract][Full Text] [Related]
11. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
[TBL] [Abstract][Full Text] [Related]
12. In vitro reactivity to a protein-bound polysaccharide PSK of peripheral blood lymphocytes from patients with gastrointestinal cancer.
Sugimachi K; Maehara Y; Kusumoto T; Okamura T; Korenaga D; Kohnoe S; Baba H; Anai H
Anticancer Res; 1995; 15(5B):2175-9. PubMed ID: 8572620
[TBL] [Abstract][Full Text] [Related]
13. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group].
Ichihashi H; Kondo T; Nakazato H
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2758-66. PubMed ID: 3307635
[TBL] [Abstract][Full Text] [Related]
14. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
Koda K; Miyazaki M; Sarashina H; Suwa T; Saito N; Suzuki M; Ogawa K; Watanabe S; Kodaira S; Nakazato H
Int J Oncol; 2003 Jul; 23(1):165-72. PubMed ID: 12792790
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Nakazato H; Koike A; Saji S; Ogawa N; Sakamoto J
Lancet; 1994 May; 343(8906):1122-6. PubMed ID: 7910230
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer.
Yoshitani S; Takashima S
Cancer Biother Radiopharm; 2009 Feb; 24(1):35-40. PubMed ID: 19243246
[TBL] [Abstract][Full Text] [Related]
18. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer.
Iino Y; Yokoe T; Maemura M; Horiguchi J; Takei H; Ohwada S; Morishita Y
Anticancer Res; 1995; 15(6B):2907-11. PubMed ID: 8669887
[TBL] [Abstract][Full Text] [Related]
19. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.
Fisher M; Yang LX
Anticancer Res; 2002; 22(3):1737-54. PubMed ID: 12168863
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer.
Nio Y; Tsubono M; Tseng CC; Morimoto H; Kawabata K; Masai Y; Shiraishi T; Imai S; Ohgaki K; Tobe T
Biotherapy; 1992; 4(2):117-28. PubMed ID: 1622733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
